Kendall Forbes Sells 346,672 Shares of Guardian Pharmacy Services (NYSE:GRDN) Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN) insider Kendall Forbes sold 346,672 shares of Guardian Pharmacy Services stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $10,289,224.96. Following the completion of the transaction, the insider directly owned 453,256 shares of the company’s stock, valued at approximately $13,452,638.08. This trade represents a 43.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Guardian Pharmacy Services Stock Performance

Shares of GRDN stock opened at $35.41 on Friday. The firm’s 50-day moving average is $32.74 and its 200-day moving average is $29.91. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of 45.98 and a beta of 0.86. Guardian Pharmacy Services, Inc. has a 52-week low of $19.17 and a 52-week high of $38.12.

Guardian Pharmacy Services (NYSE:GRDN) last issued its earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.10. The business had revenue of $397.62 million during the quarter, compared to the consensus estimate of $390.04 million. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year. Sell-side analysts predict that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Key Headlines Impacting Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: Q3 / latest quarter: GRDN beat EPS and revenue estimates (revenue +17.4% YoY), which supports growth expectations. MarketBeat GRDN summary
• Positive Sentiment: Analyst momentum: several firms (Truist, Raymond James, Oppenheimer, Stephens, Zacks) have raised targets or ratings recently, leaving a buy/strong-buy consensus and a ~$38 average target. Analyst coverage
• Neutral Sentiment: Institutional holders: several funds (Vanguard, Wellington, Brown Advisory, Franklin, Valiant) have recently adjusted positions; this shows continuing institutional interest but mixed flows. Holders data
• Neutral Sentiment: Market writeups flagged “major insider exodus,” useful for context but not new filings by itself. TipRanks article
• Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — a large block that likely pressured the stock. SEC filing
• Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — another very large director sale. SEC filing
• Negative Sentiment: Director John Ackerman sold 1,103,364 shares at ~$29.68 (~$32.7M), a ~76% reduction in his stake. SEC filing
• Negative Sentiment: Officer Fred Burke sold 671,432 shares at ~$29.68 (~$19.9M), a ~44% cut to his position. SEC filing
• Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at ~$29.68 (~$10.3M), reducing her holding by ~43%. SEC filing
• Negative Sentiment: Insider David K. Morris sold 187,855 shares at ~$29.68 (~$5.6M), cutting his position by ~42%. SEC filing
• Negative Sentiment: Major shareholder Equity Fund L.P. (Cardinal) sold 275,728 shares at ~$29.68 (~$8.2M), a ~44% stake reduction — signals significant institutional unloading. SEC filing

Institutional Investors Weigh In On Guardian Pharmacy Services

Institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue acquired a new position in shares of Guardian Pharmacy Services in the third quarter valued at approximately $30,000. Ameritas Investment Partners Inc. increased its stake in shares of Guardian Pharmacy Services by 26.5% during the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after purchasing an additional 345 shares during the period. Raymond James Financial Inc. acquired a new stake in Guardian Pharmacy Services during the 2nd quarter worth approximately $43,000. Police & Firemen s Retirement System of New Jersey lifted its holdings in Guardian Pharmacy Services by 76.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company’s stock worth $52,000 after purchasing an additional 1,062 shares during the last quarter. Finally, Strs Ohio acquired a new position in Guardian Pharmacy Services in the 4th quarter valued at $75,000.

Analyst Ratings Changes

Several brokerages have recently commented on GRDN. Weiss Ratings reiterated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research note on Monday, December 29th. Raymond James Financial reaffirmed an “outperform” rating and set a $40.00 price target on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Truist Financial lifted their price objective on shares of Guardian Pharmacy Services from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. Oppenheimer upped their price objective on shares of Guardian Pharmacy Services from $35.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Finally, Stephens increased their price objective on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $38.00.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.